Skip to main content

Advertisement

Table 2 HPV prevalence in breast cancer cases across region, HPV DNA source, and publication period

From: Inconclusive role of human papillomavirus infection in breast cancer

Variable No. of studies No. of cases Proportion(%) HPV prevalence (%) (95 % CI) P OR (95%CI) Adjusted ORa ( 95 % CI)
Total 38 2569 100 30.30(22.30–38.40)  
Region      <0.001   
Oceania 3 130 5.06 44.30(33.50–55.00)   Ref. Ref.
Asia 16 1335 51.96 35.70(20.60–50.80)   0.24(0.17–0.35) 0.21(0.14–0.32)
Europe 9 467 18.18 32.60(6.50–58.70)   0.17(0.11–0.27) 0.09(0.05–0.14)
South America 7 522 20.32 14.60(5.80–23.50)   0.14(0.09–0.21) 0.07(0.04–0.11)
North America 3 115 4.48 10.70(4.40–17.00)   0.14(0.07–0.28) 0.06(0.03–0.13)
HPV DNA source      0.08   
Fixed tissue 24 1537 59.83 27.20(17.90–36.40)   Ref. Ref.
Fresh tissue 14 1032 40.17 37.30(20.10–54.50)   0.82(0.66–1.03) 0.46(0.36–0.60)
Publication period      0   
1992-2006 14 665 25.89 42.20(25.60–58.80)   Ref. Ref.
2007-2012 24 1904 74.11 22.60(14.40–30.70)   0.37(0.30–0.46) 0.26(0.20–0.33)
  1. CI confidence ratio, OR odds ratio, Ref. reference
  2. aAdjusted for region, HPV DNA source and publication date